1 / 33

Perioperative Pain Management Using a Multi-Modal Approach

Perioperative Pain Management Using a Multi-Modal Approach. Melanie MacInnis; PharmD, RPh Clinical Pharmacist, HHS/McMaster May 2012. Learning Objectives. After this presentation, the learner should be able to: Describe the rationale of multimodal analgesia

alida
Télécharger la présentation

Perioperative Pain Management Using a Multi-Modal Approach

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Perioperative Pain Management Using a Multi-Modal Approach Melanie MacInnis; PharmD, RPh Clinical Pharmacist, HHS/McMaster May 2012

  2. Learning Objectives • After this presentation, the learner should be able to: • Describe the rationale of multimodal analgesia • Understand the role of acetaminophen, NSAIDs and gabapentin in post-operative pain control • Determine patient specific factors for prescribing a multi modal pain control regimen

  3. Pain Definitions Pain is defined by IASP as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.

  4. Analgesia Postop Pain “The major difference between iatrogenic pain and other types of pain is that iatrogenic pain is anticipated. Therefore, the physician has an excellent opportunity to deal with such pain in a planned and expeditious manner.” Brian Goldman, MD

  5. The Role of Pain Control in Postoperative Care • Prevent suffering • Hasten recovery • Influence perioperative morbidity • Decrease the development of chronic pain

  6. Chronic Pain Medications • Anti-inflammatories (NSAIDs, steroids) • Muscle relaxants • Benzodiazepines • TCAs and other anti-depressants (SSRIs, SNRIs) • Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine) • Opioids • Tramadol • IV Anti-arrhythmics (lidocaine, bretylium) • Topical formulations (capsaicin, lidocaine, NSAIDs) • Alpha 2-agonists (clonidine, guanethedine) • Cannabinoids (Nabilone) • NMDA antagonists (ketamine, methadone, memantine) • Osteoclast inhibitors (calcitonin, alendronate)

  7. Opioid Tolerance • Shortened duration and decreased intensity of analgesia, euphoria, sedation, and other CNS effects • Predictable pharmacologic adaptation • Rightward shift in the dose-response curve means increasing amount of drug to maintain the same effects • In general, the higher the daily dose, the greater the degree of tolerance • Individuals requiring >1 mg IV (3 mg PO) morphine per hour for a period of > 1 month are considered to have high-grade tolerance and withdrawal symptoms World Institute of Pain 2005; 5(1): 18-32

  8. Can J Anesth 2006; 53 (12): 1190-99

  9. Problems of Equi-Analgesic Dose Ratios of Opioids • Incomplete cross tolerance occurs during chronic opioid use • Accumulation of active metabolites can influence effect of opioids • The ratios may change according to the direction of opioid switch

  10. Strategies for Pain Control • Multimodal analgesia: balanced technique • Determine and continue baseline opioid requirements, in addition to acute pain requirements • Treat contributing co-morbidities, such as anxiety, poor sleep, nausea and constipation • Order pain medications in the acute phase routinely, rather than PRN

  11. CNS Drugs 2007; 21(3): 185-211

  12. Multi modal analgesia • Different classes of drugs exert different side effects • Side effects can be dose related • Additive/synergistic • Combinations can provide superior analgesia than either drug alone • Opioid sparing • Improved recovery, shorter hospital stay

  13. Acetaminophen • Very weak COX inhibitor • No appreciable anti-inflammatory or NSAID side effects • Liver metabolism • 4g/d in healthy adults • Lower doses: • Liver disease (2g/d) • Alcoholism (2g/d) • Frail elderly (3.2g/d)

  14. “Tylenol” • Always confirm with patients • Extra strength tylenol ≠ tylenol with codeine • PRN vs RTC • Acetaminophen as part of multi-modal analgesia minimizes opioid requirements by 20%

  15. NSAIDS • Effective for post operative pain • MOA: • Inhibit cyclo-oxygenase (COX) in the periphery and spinal column • Several variants of COX enzyme • Influence platelet function, GI mucosa, and renal function, CV risk • Selecting the COX variant to avoid side effects

  16. Adverse effects • Platelet dysfunction • NSAIDs alone not a risk for spinal hematoma • GI ulceration • Nephrotoxicity • Headache, tinnitus, abdominal pain, rash, hyperkalemia, asthma

  17. Renal function • Serum creatinine is used as a surrogate • NB: extremes of body weight and nourishment • Baseline SCr and while on NSAID • Also urea nitrogen, I/O • Cockroft Gault • eGFR

  18. SCr = (140-age)(kg) x 0.85 if female (SCr)(72) http://nephron.com/cgi-bin/CGSI.cgi OR www.globalrph.com (from calculators menu select CrCl multi-calc under C)

  19. Monitoring for NSAIDs • CBC (plts), SCr, BUN, lytes • Absolute contra-indication • GI ulcer, hx of PUD/GUD; CHF; low platelets; CrCl less than 30ml/min • Relative contraindication • Fracture, GERD, age

  20. Celecoxib: sulfa allergy; only COX-2 selective, 200mg/d max • Ketorolac: only IV product, po • Ibuprofen: suspension, OTC or rx, po • Naproxen: OTC or rx, po or pr

  21. NSAIDs + Acetaminophen • 21 studies • 1909 patients • Ibuprofen, diclofenac, ketorolac, aspirin • Lower pain scores • Lower supplemental analgesic requirements • Better global pain relief Anesth Analg 2010; 110:1170-9

  22. NSAIDs + Acetaminophen

  23. NSAIDs + Acetaminophen • No evidence of increased side effects • If morphine rescue required; higher incidence of N/V

  24. Analgesic Efficacy • NNT calculated for at least 50% pain relief over 4-6h compared to placebo • Oral, single dose • Moderate to Severe pain • All are oral unless otherwise specified • Doses in mg

  25. Gabapentinoids • Gabapentin (Neurontin) and pregabalin (Lyrica) • Enhance the inhibitory pain pathway long term • Impact sodium gated channels of nerves in the periphery • Prevent hyperalgesia postoperatively • Modify transmission of nerve impulses • Can prevent persistent post surgical pain at 3-6 months

  26. Gabapentinoids • Role in post-operative treatment is unclear • Can reduce pain intensity and opioid consumption • Optimal dose and duration unknown • Gabapentin: 300-1200mg pre op, post op 100-300mg variety of dosing strategies • Pregabalin: 150-300mg pre-op, post op doses 50mg-150mg of durations 24h – 2 weeks • No influence on prevention of PONV

  27. Gabapentinoids • Renally eliminated • SCr needed baseline and after initiation • Dose reduction in renal impairment • After long term use needs to be tapered to DC (seizure risk) • In elderly can cause confusion, sedation, dysphoria

  28. Take Home Points • Multimodal analgesia can help improve pain control and minimize side effects • Persistent postsurgical pain may be influenced by improved acute pain control • Order routine pain medications initially for moderate to severe pain (rather than PRN)

  29. Take Home Points • Patient specific factors need to be considered in prescribing the best post-operative analgesic regimen • Around the clock NSAIDS + acetaminophen are effective and minimize opioid use • The role of gabapentinoids is unclear in post operative pain control

  30. Thank you. Questions and Comments.

More Related